NCT00102193已完成3 期
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 168
- 试验地点
- 74
- 主要终点
- Safety will be evaluated by determining the frequency and severity of adverse events
研究概览
简要总结
The purpose of this study is to demonstrate the safety and effectiveness of the Adacolumn Apheresis System to treat the signs and symptoms of ulcerative colitis.
详细描述
Trial Features:
- Non-drug therapy
- Most patients can remain on current treatment regimen, including prednisone, budesonide and medications such as Asacol (mesalamine), Pentasa (mesalamine), Colazal (balsalazide disodium) and Dipentum (olsalazine sodium) throughout the study
Components of the Study:
- Study length is 24 weeks, which includes a screening visit, ten treatment visits over nine weeks and 4 follow-up appointments
- Physical exams, laboratory tests and disease assessments conducted at no charge to the patient
- 2:1 Randomization (treatment:sham)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Moderate to severe active ulcerative colitis with colonic involvement with ulcerative colitis beyond 15 cm of the anal verge
- •Adequate peripheral venous access to allow for completion of the apheresis treatments
- •Receiving one or more of the following medical therapies:
- •*sulfasalazine, *mesalamine and other 5-ASA agents, *prednisone or 6-mercaptopurine or azathioprine OR Have not received the above medical therapies due to intolerance or demonstrated non-response
- •Agree to participate in the required follow-up visits
- •Able to complete a diary
- •Signed written informed consent document and authorization for use of protected health information
排除标准
- •Evidence of toxic megacolon
- •Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks
- •Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis
- •Requiring in-patient hospitalization
- •A history of allergic reaction to heparin or heparin-induced thrombocytopenia
- •A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures
- •A history of severe cardiovascular or peripheral arterial diseases
- •A history of cerebral vascular diseases
- •Liver diseases
- •Renal insufficiency
- •Insulin-dependent Type I or Type II diabetes
- •Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment
- •Any hypercoagulable disorder
- •Known infection with Hepatitis B or C, or HIV
- •Severe anemia
- •Leukopenia or granulocytopenia
- •Evidence of current systemic infection
- •Malignancy
- •Pregnant, lactating or planning to become pregnant during the course of the investigational study
- •Used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic
结局指标
主要结局
Safety will be evaluated by determining the frequency and severity of adverse events
Effectiveness will be primarily evaluated at Week 12 by disease activity index (DAI) score
次要结局
未报告次要终点
研究者
研究点 (74)
Loading locations...
相似试验
已完成
3 期
Study for the Treatment of Crohn's Disease With AdacolumnCrohn's DiseaseNCT00162942Otsuka America Pharmaceutical235
已完成
2 期
A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled AsthmaAsthmaNCT01730027Pulmagen Therapeutics248
已完成
1 期
Bioequivalence of Adapalene Topical Gel in Patients With Acne VulgarisAcne VulgarisNCT01182636Teva Pharmaceuticals USA601
进行中（未招募）
3 期
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionGiant Cell ArteritisNCT05380453Novartis Pharmaceuticals151
已完成
1 期
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's ParticipantsParkinson's DiseaseNCT05603312MeiraGTx, LLC14